Last reviewed · How we verify
Methylene Blue MMX®
Methylene Blue MMX® is a Mitochondrial function enhancer / Antioxidant Small molecule drug developed by Cosmo Technologies Ltd. It is currently in Phase 3 development for Mild cognitive impairment, Alzheimer's disease. Also known as: Investigational Product: Methylene Blue MMX® modified release tablets, Active Ingredient: Methylene Blue.
Methylene Blue MMX is a modified-release formulation of methylene blue that acts as a mitochondrial function enhancer and antioxidant to improve cognitive and neurological outcomes.
Methylene Blue MMX is a modified-release formulation of methylene blue that acts as a mitochondrial function enhancer and antioxidant to improve cognitive and neurological outcomes. Used for Mild cognitive impairment, Alzheimer's disease.
At a glance
| Generic name | Methylene Blue MMX® |
|---|---|
| Also known as | Investigational Product: Methylene Blue MMX® modified release tablets, Active Ingredient: Methylene Blue |
| Sponsor | Cosmo Technologies Ltd |
| Drug class | Mitochondrial function enhancer / Antioxidant |
| Target | Mitochondrial electron transport chain; cytochrome c oxidase |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Methylene blue is a redox-active compound that crosses the blood-brain barrier and enhances mitochondrial electron transport chain function, reducing oxidative stress and neuroinflammation. The MMX (multi-matrix extended-release) formulation provides sustained delivery to optimize bioavailability and therapeutic effect in the central nervous system.
Approved indications
- Mild cognitive impairment
- Alzheimer's disease
Common side effects
- Blue discoloration of urine and skin
- Gastrointestinal disturbances
- Headache
Key clinical trials
- Colon Staining Efficacy of Single Oral Doses of Methylene Blue MMX (PHASE2)
- The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methylene Blue MMX® CI brief — competitive landscape report
- Methylene Blue MMX® updates RSS · CI watch RSS
- Cosmo Technologies Ltd portfolio CI
Frequently asked questions about Methylene Blue MMX®
What is Methylene Blue MMX®?
How does Methylene Blue MMX® work?
What is Methylene Blue MMX® used for?
Who makes Methylene Blue MMX®?
Is Methylene Blue MMX® also known as anything else?
What drug class is Methylene Blue MMX® in?
What development phase is Methylene Blue MMX® in?
What are the side effects of Methylene Blue MMX®?
What does Methylene Blue MMX® target?
Related
- Drug class: All Mitochondrial function enhancer / Antioxidant drugs
- Target: All drugs targeting Mitochondrial electron transport chain; cytochrome c oxidase
- Manufacturer: Cosmo Technologies Ltd — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Mild cognitive impairment
- Indication: Drugs for Alzheimer's disease
- Also known as: Investigational Product: Methylene Blue MMX® modified release tablets, Active Ingredient: Methylene Blue
- Compare: Methylene Blue MMX® vs similar drugs
- Pricing: Methylene Blue MMX® cost, discount & access